Laura Eadie
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Laura Eadie is a mid-career researcher having completed her PhD in Medicine in 2013 with a Dean’s Commendation. Laura’s research has always centred on translating laboratory findings to improve patient outcomes. She has spent ten+ years researching modes of resistance to chronic myeloid leukaemia drugs with her efforts resulting in nine first-author publications and presentations at over 25 national and international meetings. She is the tenth recipient of the Peter Nelson Leukaemia Research Fellowship and her research now focuses on high-risk acute lymphoblastic leukaemia (ALL). She is a passionate science communicator and advocate for women in STEM careers. Laura was a 2016 Fulbright Postdoctoral Fellow and was invited to take part in the first TEDx-Fulbright Adelaide event (2019).
Acute Lymphoblastic Leukaemia (ALL) is an extremely heterogeneous disease with subtypes of patients exhibiting a diverse range of genetic mutations. Certain subtypes of ALL can be treated with drugs already in clinical use. Laura undertook her Fulbright fellowship (2016-2017) at St. Jude Children’s Research Hospital in Memphis, Tennessee where she learned mouse models of high-risk ALL. Laura is now leading in vivo mouse studies for high-risk ALL with a specific focus on T-cell ALL. Laura’s research seeks to pave the way for alternative T-ALL therapies that are more effective and have fewer long-term side effects. She is using cutting edge laboratory models to evaluate precision medicine treatment strategies tailored to individual patients. Her current funding will help her and her team create a repository of cells, enabling experimentation and evaluation of the success of different T-ALL targeted therapies.
Long term, Laura aims to provide clinicians with a suite of new and re-purposed FDA-approved drugs, which will be able to effectively treat the different genetic lesions associated with T-ALL.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Acute Lymphoblastic Leukaemia (ALL) is one of the biggest causes of non-traumatic death in children and relapsed T-cell ALL (T-ALL) is an extremely high risk disease. Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. More effective, less toxic treatments are urgently needed for when a patient fails their front-line chemotherapy. Dr Eadie is SAHMRI's T-ALL research leader and her team creates humanised mouse avatars from individual patient’s leukaemic cells to use in pre-clinical drug trials. Combined with genomic sequencing to identify a patient’s leukaemia-causing mutations, these models allow Dr Eadie to discover more effective therapeutic options targeted to each individual patient’s leukaemia.
T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge.
Dr Eadie's long-term research goal is to identify new and re-purposed drugs which effectively treat the different genetic lesions associated with T-ALL. Her team's findings will ultimately provide clinicians with an arsenal of alternative treatment options and hope for patients who have relapsed.
Research Projects - Dr Laura Eadie
Title: Evaluation of novel alterations in pre-clinical models of T-cell Acute Lymphoblastic Leukaemia (T-ALL)
Project description:
Dr Eadie's research program utilises genomic sequencing to identify novel and targetable T-ALL alterations to accelerate a transition towards precision medicine to improve clinical outcomes. Dr Eadie's Research Group is part of the SAHMRI ALL Genomics and Functional Genomics/Biology Laboratory led by Prof Deborah White (leader, SAHMRI Precision Cancer Medicine Theme). Together, with the ALL bioinformatic team, Dr Eadie has curated the largest genomic sequencing database of T-ALL patients in Australia. Dr Eadie has identified novel leukaemia-causing alterations as well as new treatment options for several high-risk ALL subtypes.
SAHMRI's ALL Research laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients from Australia and New Zealand. Identification of novel and recurrent genomic alterations is ongoing and we have projects available to characterise these alterations in vitro and in vivo.
The over-arching focus of Dr Eadie's research program is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models are used to (1) examine re-purposing drugs and test novel therapies; and (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease.
Projects available for: HDR: Mphil / PhD
Location: SAHMRI
Research project start: Semester 1 or 2
Special requirements: Police Clearance
-
Appointments
Date Position Institution name 2020 - ongoing Affiliate Senior Lecturer University of Adelaide 2019 - ongoing Peter Nelson Post-doctoral Research Fellow SAHMRI 2016 - 2017 Post-doctoral Research Associate St. Jude Children's Research Hospital 2014 - 2020 Affiliate Lecturer University of Adelaide 2013 - 2019 Post-doctoral Researcher SAHMRI 2013 - 2013 Post-doctoral Researcher SA Pathology -
Awards and Achievements
Date Type Title Institution Name Country Amount 2020 Award American Society of Hematology (ASH) Abstract Achievement Award American Society of Hematology United States - 2020 Award CASS Foundation Travel Grant The CASS Foundation Australia $3500 2019 Invitation Spot the Bull Science The Science Nation Australia - 2019 Award The Hospital Research Foundation Research Travel Awards The Hospital Research Foundation Australia $4000 2019 Invitation TEDxFulbright Oration: The Secret Life of a Scientist SAHMR Australia - 2019 Fellowship Peter Nelson Leukaemia Research Fellowship SAHRMI Australia 300000 2019 Fellowship Cancer Council SA Beat Cancer Project Mid-Career Cancer Research Fellowship (unable to accept) SAHMRI Australia 300000 2018 Invitation Invited Speaker: Early/Mid-Career Researcher Seminar Series The University of Adelaide Australia - 2016 Invitation Judge: European Molecular Biology Laboratory (EMBL) Australian Postgraduate Symposium (EAPS) - - - 2016 Invitation Invited Speaker: 18th Annual ESH-iCMLF International Conference on CML – Biology and Therapy - - - 2016 Invitation Invited Speaker: 18th Annual ESH-iCMLF International Conference on CML – Biology and Therapy - - - 2016 Scholarship Australian-American Fulbright Postdoctoral Scholarship - - $38, 500 2016 Invitation Invited Speaker: International Conference on Cancer Immunology and Immunotherapy - - - 2016 Fellowship Endeavour Research Fellowship (unable to accept) - - 23 000 2013 Award Dean’s Commendation for Doctoral Thesis Excellence - - - 2011 Award HSANZ Non-Member Travel Grant - - 1000 2010 Award HSANZ Non-Member Travel Grant - - 1500 2010 Award New Scientist Award for Science and Technology in Society - - 1000 2009 Scholarship Leukaemia Foundation of Australia PhD Scholarship - - 157 500 2009 Scholarship Dawes Top-up Scholarship - - 17 500 2009 Scholarship Baillieu Supplementary Research Scholarship - - 30 000 2009 Scholarship NHMRC Biomedical Postgraduate Scholarship (unable to accept) - - 65 598 2009 Scholarship Australian Postgraduate Award (unable to accept) - - 61 281 2008 Award HSANZ Non-Member Travel Grant - - 1000 2006 Award Australasian Society for HIV Medicine Junior Researcher Award - - - 2006 Scholarship Royal Adelaide Hospital Research Committee Honours Scholarship - - 5000 2005 Scholarship Molecular Plant Breeding Cooperative Research Centre Summer Scholarship - - 1500 2004 Honour Admittance to the Golden Key International Honour Society - - - -
Education
Date Institution name Country Title 2009 - 2013 University of Adelaide Australia PhD in Medicine 2006 - 2006 University of Adelaide Australia Honours Degree of Bachelor of Science 2003 - 2005 University of Adelaide, Adelaide Australia Bachelor of Science -
Postgraduate Training
Date Title Institution Country 2016 - 2017 Fulbright Post-doctoral Research Scholarship St. Jude Children's Research Hospital United States -
Research Interests
-
Journals
-
Conference Papers
Year Citation 2020 Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020 (2020). In HemaSphere Vol. 4 (pp. 1-1168). Wiley.
2018 Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins.
2015 Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology.
2013 Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology.
2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology.
2008 White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS32008 White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology.
2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS72007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology.
2005 Keiper, F., Scott, L., Eadie, L., Hayden, M., & Wallwork, H. (2005). Microsatellite (SSR) diversity among Australian Rhynchosporium secalis isolates. In 12th Australian Barley Technical Symposium Conference Proceedings, 11-14 September 2005 [CD-ROM] (pp. 6 pages). Hobart: Australian Barley Association. -
Conference Items
Year Citation 2022 Thomson, A., Rehn, J., Heatley, S., Eadie, L., McClure, B., Page, E., . . . White, D. (2022). Benchmarking the detection rate of IGH gene fusions in B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) Conference. 2021 Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2021). Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy. 2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). 2020 Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting). 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting). 2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia. 2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT. 2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT. 2020 Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2020 Forgione, M. O., McClure, B. J., Eadie, L. N., & White, D. L. (2020). CD44 and its ligand osteopontin are upregulated specifically in KMT2A-AFF1 T-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference). 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent activation of JAK/STAT signaling plays an important role in in vitro Jaki resistance in TYK2-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of 62nd Annual Meeting of the American Society of Hematology. San Diego, California (virtual conference). 2020 Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY.
WoS12020 Tavakoli, P., Eadie, L. N., Heatley, S. L., Bruning, J. B., & White, D. L. (2020). Persistent Activation of JAK/STAT Signaling Plays an Important Role in<i>in Vitro</i>Jaki Resistance in <i>TYK2</i>-rearranged B-Cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY.
2019 Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology.
2019 Tavakoli, P. S., Eadie, L., Heatley, S. L., & White, D. L. (2019). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting 2019. Christchurch, New Zealand. 2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany. 2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2019 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. 2019 Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. 2018 Eadie, L. N., Mullighan, C., & White, D. L. (2018). Mutations to the transcription factor MYB alter cellular localization and decrease degradation likely enhancing oncogenicity in patients with T-cell ALL. Poster session presented at the meeting of NDLR. 2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of ASMR. 2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of SAHMRI Scientific Seminar. 2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of 12th Annual Florey postgraduate Conference. 2018 Tavakoli Shiraz, P., Eadie, L. N., Heatley, S. L., & White, D. L. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates in vitro efficacy against a novel MYB-TYK2 fusion protein in acute lymphoblastic leukaemia cells. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. 2016 Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA. 2016 Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA. 2016 Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS12016 Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY.
2016 Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD. 2016 Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD. 2016 Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA. 2016 Leow, B., Eadie, L. N., Leclercq, T., & White, D. L. (2016). Drug resistance in CML: heterogeneity, selection, and clonal architecture. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12013 White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA.
Date: June 2023 - June 2026
Project Name: “Modelling co-occurring mutations in T-ALL to enhance treatment options and maximise the power of next generation sequencing”
Chief Investigator A: Laura Eadie
Funding Body: Cancer Council South Australia Beat Cancer Project
Amount: $599,610
Date: January 2023 - December 2024
Project Name: “Modelling co-occurring mutations in T-ALL to enhance treatment options and maximise the power of next generation sequencing”
Chief Investigator A: Laura Eadie
Funding Body: SAHMRI Early and Mid-Career Researcher Seed Funding Grant
Amount: $30,000
Date: December 2022
Chief Investigator A: Laura Eadie
Funding Body: International Thermo Fisher Scientific Cancer Research Grant
Amount: in kind funding, ~$25,000
Date: January 2021 - December 2024
Project Name: "Adolescents with Acute Lymphoblastic Leukaemia: Focussing on the gut microbiota, its role in therapeutic response and potential as an effective adjunct therapeutic in this High-Risk group"
Chief Investigator G: Laura Eadie
Funding Body: MRFF – Emerging Priorities and Consumer Driven Research Initiative Childhood Cancer Research
Amount: $1,292,871
Date: January 2019 - June 2023
Project Name: “Preclinical modelling of T-cell Acute Lymphoblastic Leukaemia – defining targeted therapies and preventing treatment resistance”
Chief Investigator A: Laura Eadie
Funding Body: Peter Nelson Leukaemia Research Fellowship Fund
Amount: $659,970
Date: unable to accept due to duplicate project funding
Project Name: “Preclinical modelling of T-cell Acute Lymphoblastic Leukaemia – defining targeted therapies and preventing treatment resistance”
Chief Investigator A: Laura Eadie
Funding Body: Cancer Council South Australia Beat Cancer Project
Amount: $599,971
Date: January 2019 - December 2020
Project Name: “Acute Lymphoblastic Leukaemia: Understanding the factors that determine response to new immune-based therapies”
Chief Investigator A: Deborah White
Associate Investigator: Laura Eadie
Funding Body: Tour de Cure
Amount: $100, 000
Date: January 2017 - December 2018
Project Name: “Using in vivo modelling to investigate therapeutic approaches to reverse/prevent disease resistance in children with high-risk Ph-like B-ALL and T-ALL treated with targeted therapies”
Application Number: 171412
Chief Investigator A: Laura Eadie
Associate Investigator: Deborah White
Funding Body: Channel 7 Children’s Research Foundation
Amount: $75, 000
Date: 2023 onwards
Adelaide University Lecturer
BIOCHEMISTRY III: Cancer, Stem Cells and Development III
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Principal Supervisor Modelling co-occurring mutations in T-cell Acute Lymphoblastic Leukaemia to enhance treatment options and maximise the power of next generation sequencing Doctor of Philosophy Doctorate Full Time Mr Maxim Jon Buckley -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2022 Co-Supervisor Characterising KMT2A and MLLT10 Rearranged Acute Lymphoblastic Leukaemia Doctor of Philosophy Doctorate Full Time Miss Michelle Olivia Forgione 2017 - 2021 Co-Supervisor Characterising the novel MYB-TYK2 fusion gene in high-risk acute lymphoblastic leukaemia: oncogenic potential, effective therapeutic strategies and In vitro modelling of drug resistance mechanisms Doctor of Philosophy Doctorate Full Time Miss Paniz Tavakoli Shirazi 2015 - 2019 Co-Supervisor Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Mr Benjamin Chia Sing Leow -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2020 - 2020 Principal Supervisor Investigation of oncogenic fusion genes in leukaemia and evaluation of the efficacy of ABL001 South Australian Health & Medical Research Institute - Honours Full Time Elias Lagonik 2018 - ongoing Principal Supervisor Investigating the efficacy of novel and combination therapies in Ph-like ALL South Australian Health & Medical Research Institute - Honours Full Time Caitlin Schutz 2014 - 2014 Co-Supervisor The effect of the T315I mutation on treatment failure in Chronic Myeloid Leukemia: a mere case of drug binding efficiency? South Australian Health & Medical Research Institute HONOURS DEGREE of BACHELOR OF HEALTH SCIENCES Honours Full Time Benjamin Leow -
Mentoring
Date Topic Location Name 2020 - 2020 Careers Mentoring University of Adelaide Hannah Bonham 2020 - 2020 Careers Mentoring University of Adelaide Mogana Reckdharajkumar
-
Committee Memberships
Date Role Committee Institution Country 2020 - 2021 Representative Australian Society for Medical Research SA Committee Australian Society for Medical Research Australia 2019 - 2019 Treasurer Australian Society for Medical Research SA Committee Australian Society for Medical Research Australia -
Memberships
Date Role Membership Country 2017 - ongoing Member National Postdoctoral Association United States 2016 - ongoing Member Australian Society for Medical Research (ASMR) Australia 2015 - 2016 Member YWCA - 2006 - 2007 Member Australasian Society for HIV Medicine (ASHM) Australia -
Presentation
Date Topic Presented at Institution Country 2019 - 2019 The Secret Life of a Scientist TEDxFulbright, Adelaide 2019 South Australian Health & Medical Research Institute Australia
Connect With Me
External Profiles
